Granted Patent
B2
US 9,790,174 · App. 15/261,174 · Granted Oct 17, 2017
Kinase inhibitors
C07C317/48A61K31/44A61K31/444A61K31/4427A61K31/505A61K31/506A61K31/5377A61K31/541A61K31/551A61K31/553C07C311/08C07C317/28C07D211/86C07D213/74C07D233/90C07D239/47C07D401/12C07D403/12C07D405/12C07D405/14C07D413/12
View Patent ↗
Loading inventors, assignments & file history…
Abstract
There are provided compounds of formula IIb, wherein LG 1 represents imidazolyl, chloro or aryloxy, which compounds are useful in the preparation of compounds that have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
Claims (3)
1. A compound of formula IIb,
wherein LG 1 represents imidazolyl, chloro or aryloxy.
2. A compound of formula IIb, as claimed in claim 1 , wherein LG 1 represents phenoxy.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 10, 2020
From: TOPIVERT PHARMA LIMITED
To: OXULAR ACQUISITIONS LIMITED
Reel/Frame 054610/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 10, 2018
From: RESPIVERT LIMITED
To: TOPIVERT PHARMA LIMITED
Reel/Frame 047725/0470 →
Priority Claims (3)
GB 1305945.6
· Apr 2, 2013
· national
GB 1322678.2
· Dec 20, 2013
· national
GB 1402647.0
· Feb 14, 2014
· national
Continuity (2)